Biotech | August 17, 2021
Indian pharma’s vaccine opportunity at US $ 10-11 billion
Domestic market and developing countries will need doses of Indian vaccines
Domestic market and developing countries will need doses of Indian vaccines
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Anti-malaria API facility will be operational in 15-18 months
Filing for WHO Emergency Use Authorisation this month
India business contributes to a stellar performance
Robust demand for the product across the Middle East, Africa and Latin America
Drug formulations and biologics make impressive gains
India business is growing as per projections; whereas US business will bounce back soon.
The Cephalosporin Injectables plant has a total capacity of 26.4 million vials per year while Ethiopia is having a demand for 16 million vials
Vikas Lifecare has already paid Rs. 25 million to the Advik bankers till date and the remaining amount shall also be paid within July 2021, making Advik a debt free company
Subscribe To Our Newsletter & Stay Updated
